Phase I Pilot Study of RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Latest Information Update: 30 Apr 2026
At a glance
- Drugs Vusolimogene oderparepvec (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 13 Apr 2026 Planned End Date changed from 31 Mar 2027 to 31 Mar 2029.
- 13 Apr 2026 Planned primary completion date changed from 31 Mar 2026 to 31 Mar 2028.
- 10 Apr 2025 Planned End Date changed from 31 Jul 2028 to 31 Mar 2027.